Tvardi Therapeutics
TVRD
170 hedge funds and large institutions have $457M invested in Tvardi Therapeutics in 2021 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 50 increasing their positions, 53 reducing their positions, and 29 closing their positions.
63% more call options, than puts
Call options by funds: $9.69M | Put options by funds: $5.95M
3% more capital invested
Capital invested by funds: $444M → $457M (+$13M)
6% less repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 53
2% less funds holding
Funds holding: 174 → 170 (-4)
3.11% less ownership
Funds ownership: 62.2% → 59.09% (-3.1%)
10% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 29
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DGI
Disciplined Growth Investors
Minneapolis,
Minnesota
|
+$13.9M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$7.54M |
| 3 |
KCM
Kingdon Capital Management
New York
|
+$3.95M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.7M |
| 5 |
Jane Street
New York
|
+$2.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCP
Rho Capital Partners
New York
|
-$20.9M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$10.4M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$4.5M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
-$3.64M |
| 5 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$3.58M |
TVRD Hedge Fund Activity: Q3 2021 in Review
170 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q3 2021, worth a combined $457M — up 2.9% from $444M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of TVRD and 26 opened new positions — a net loss of 3 holders — while 53 trimmed existing stakes and 50 added.
The largest buyer was Disciplined Growth Investors, adding an estimated $13.9M. The largest seller was Rho Capital Partners, exiting entirely with an estimated $20.9M sold.
- 170 institutional investors held Tvardi Therapeutics (TVRD) as of Q3 2021, down from 174 in Q2 2021.
- Funds reported $457M of Tvardi Therapeutics stock for Q3 2021, up 2.9% quarter-over-quarter.
- 26 funds opened new Tvardi Therapeutics positions in Q3 2021 and 29 closed out, a net change of -3 holders.
- The largest Tvardi Therapeutics buyer in Q3 2021 was Disciplined Growth Investors, an estimated $13.9M added.
- The largest Tvardi Therapeutics seller in Q3 2021 was Rho Capital Partners, an estimated $20.9M sold.
Based on aggregated 13F filings for Q3 2021.